Radiofrequency Ablation of Invasive Breast Carcinomas: A Phase II Trial
Background Local ablative therapy of breast cancer represents the next frontier in the minimally invasive breast-conservation treatment. We conducted a phase II trial to evaluate radiofrequency ablation (RFA) of invasive breast carcinomas. Methods Consecutive patients from two Mexican Institutions w...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2008-06, Vol.15 (6), p.1689-1695 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1695 |
|---|---|
| container_issue | 6 |
| container_start_page | 1689 |
| container_title | Annals of surgical oncology |
| container_volume | 15 |
| creator | Medina-Franco, Heriberto Soto-Germes, Santos Ulloa-Gómez, José L. Romero-Trejo, Cecilia Uribe, Norma Ramirez-Alvarado, Carlos A. Robles-Vidal, Carlos |
| description | Background
Local ablative therapy of breast cancer represents the next frontier in the minimally invasive breast-conservation treatment. We conducted a phase II trial to evaluate radiofrequency ablation (RFA) of invasive breast carcinomas.
Methods
Consecutive patients from two Mexican Institutions with invasive breast cancers |
| doi_str_mv | 10.1245/s10434-008-9875-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69194089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69194089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-97991824be898dd5ca73d718eb19c4f43b579ed2f14a29b53a1df06736d63d113</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlZ_gBcJHrytZvKxSbzVorVQUKSeQ3aT1S3b3Zq0hf57U1ooCJ4mzDzzZngQugZyD5SLhwiEM54RojKtpMj4CeqDSB2eKzhNb5KnCc1FD13EOCcEJCPiHPVAsZwRSfto_GFd3VXB_6x9W27xsGjsqu5a3FV40m5srDcePwVv4wqPbCjrtlvY-IiH-P3bRo8nEzwLtW0u0Vllm-ivDnWAPl-eZ6PXbPo2noyG06zkTKwyLbUGRXnhlVbOidJK5iQoX4AuecVZIaT2jlbALdWFYBZcRXLJcpczB8AG6G6fuwxdOjmuzKKOpW8a2_puHU2uQXOidAJv_4Dzbh3adJuhVDIpk7AEwR4qQxdj8JVZhnphw9YAMTvFZq_YJMVmp9jwtHNzCF4XC--OGwenCaB7IKZR--XD8ef_U38B3wOEYQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227377875</pqid></control><display><type>article</type><title>Radiofrequency Ablation of Invasive Breast Carcinomas: A Phase II Trial</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Medina-Franco, Heriberto ; Soto-Germes, Santos ; Ulloa-Gómez, José L. ; Romero-Trejo, Cecilia ; Uribe, Norma ; Ramirez-Alvarado, Carlos A. ; Robles-Vidal, Carlos</creator><creatorcontrib>Medina-Franco, Heriberto ; Soto-Germes, Santos ; Ulloa-Gómez, José L. ; Romero-Trejo, Cecilia ; Uribe, Norma ; Ramirez-Alvarado, Carlos A. ; Robles-Vidal, Carlos</creatorcontrib><description>Background
Local ablative therapy of breast cancer represents the next frontier in the minimally invasive breast-conservation treatment. We conducted a phase II trial to evaluate radiofrequency ablation (RFA) of invasive breast carcinomas.
Methods
Consecutive patients from two Mexican Institutions with invasive breast cancers < 4 cm, with no multicentric tumors and no previous chemotherapy were included in this trial. Under ultrasound guidance, the tumor and a 5 mm margin of surrounding breast tissue were ablated with saline-cooled RFA electrode followed by surgical resection. Routine pathologic analysis and viability evaluation with NADPH-diaphorase stain were performed to assess tumor ablation. Procedure-associated morbidity was recorded.
Results
Twenty-five patients were included. Mean patient age was 55.3 years (range 42–89 years). Mean tumor size was 2.08 cm (range 0.9–3.8 cm). Fourteen tumors (56%) were <2 cm. The mean ablation time was 11 minutes using a mean power of 35 W. During ablation, the tumors become progressively echogenic that corresponded with the region of severe RFA injury at pathologic examination. Of the 25 patients treated, NADPH stain showed no evidence of viable malignant cells in 19 patients (76%), with significant difference between tumors <2 cm (complete necrosis in 13 of 14 cases, 92.8%) vs. those >2 cm (complete necrosis 6 of 11 cases, 54.5%) (
P
< .05). No significant morbidity was recorded.
Conclusions
RFA is a promising minimally invasive treatment of small breast carcinomas, as it can achieve effective cell killing with a low complication rate. Further studies are necessary to optimize the technique and evaluate its future role as local therapy for breast cancer.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-008-9875-4</identifier><identifier>PMID: 18363072</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms - therapy ; Breast Oncology ; Carcinoma, Ductal, Breast - therapy ; Catheter Ablation ; Female ; Humans ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Surgery ; Surgical Oncology ; Treatment Outcome</subject><ispartof>Annals of surgical oncology, 2008-06, Vol.15 (6), p.1689-1695</ispartof><rights>Society of Surgical Oncology 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-97991824be898dd5ca73d718eb19c4f43b579ed2f14a29b53a1df06736d63d113</citedby><cites>FETCH-LOGICAL-c435t-97991824be898dd5ca73d718eb19c4f43b579ed2f14a29b53a1df06736d63d113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1245/s10434-008-9875-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1245/s10434-008-9875-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18363072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Medina-Franco, Heriberto</creatorcontrib><creatorcontrib>Soto-Germes, Santos</creatorcontrib><creatorcontrib>Ulloa-Gómez, José L.</creatorcontrib><creatorcontrib>Romero-Trejo, Cecilia</creatorcontrib><creatorcontrib>Uribe, Norma</creatorcontrib><creatorcontrib>Ramirez-Alvarado, Carlos A.</creatorcontrib><creatorcontrib>Robles-Vidal, Carlos</creatorcontrib><title>Radiofrequency Ablation of Invasive Breast Carcinomas: A Phase II Trial</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
Local ablative therapy of breast cancer represents the next frontier in the minimally invasive breast-conservation treatment. We conducted a phase II trial to evaluate radiofrequency ablation (RFA) of invasive breast carcinomas.
Methods
Consecutive patients from two Mexican Institutions with invasive breast cancers < 4 cm, with no multicentric tumors and no previous chemotherapy were included in this trial. Under ultrasound guidance, the tumor and a 5 mm margin of surrounding breast tissue were ablated with saline-cooled RFA electrode followed by surgical resection. Routine pathologic analysis and viability evaluation with NADPH-diaphorase stain were performed to assess tumor ablation. Procedure-associated morbidity was recorded.
Results
Twenty-five patients were included. Mean patient age was 55.3 years (range 42–89 years). Mean tumor size was 2.08 cm (range 0.9–3.8 cm). Fourteen tumors (56%) were <2 cm. The mean ablation time was 11 minutes using a mean power of 35 W. During ablation, the tumors become progressively echogenic that corresponded with the region of severe RFA injury at pathologic examination. Of the 25 patients treated, NADPH stain showed no evidence of viable malignant cells in 19 patients (76%), with significant difference between tumors <2 cm (complete necrosis in 13 of 14 cases, 92.8%) vs. those >2 cm (complete necrosis 6 of 11 cases, 54.5%) (
P
< .05). No significant morbidity was recorded.
Conclusions
RFA is a promising minimally invasive treatment of small breast carcinomas, as it can achieve effective cell killing with a low complication rate. Further studies are necessary to optimize the technique and evaluate its future role as local therapy for breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Breast Neoplasms - therapy</subject><subject>Breast Oncology</subject><subject>Carcinoma, Ductal, Breast - therapy</subject><subject>Catheter Ablation</subject><subject>Female</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Treatment Outcome</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1LAzEQhoMotlZ_gBcJHrytZvKxSbzVorVQUKSeQ3aT1S3b3Zq0hf57U1ooCJ4mzDzzZngQugZyD5SLhwiEM54RojKtpMj4CeqDSB2eKzhNb5KnCc1FD13EOCcEJCPiHPVAsZwRSfto_GFd3VXB_6x9W27xsGjsqu5a3FV40m5srDcePwVv4wqPbCjrtlvY-IiH-P3bRo8nEzwLtW0u0Vllm-ivDnWAPl-eZ6PXbPo2noyG06zkTKwyLbUGRXnhlVbOidJK5iQoX4AuecVZIaT2jlbALdWFYBZcRXLJcpczB8AG6G6fuwxdOjmuzKKOpW8a2_puHU2uQXOidAJv_4Dzbh3adJuhVDIpk7AEwR4qQxdj8JVZhnphw9YAMTvFZq_YJMVmp9jwtHNzCF4XC--OGwenCaB7IKZR--XD8ef_U38B3wOEYQ</recordid><startdate>20080601</startdate><enddate>20080601</enddate><creator>Medina-Franco, Heriberto</creator><creator>Soto-Germes, Santos</creator><creator>Ulloa-Gómez, José L.</creator><creator>Romero-Trejo, Cecilia</creator><creator>Uribe, Norma</creator><creator>Ramirez-Alvarado, Carlos A.</creator><creator>Robles-Vidal, Carlos</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20080601</creationdate><title>Radiofrequency Ablation of Invasive Breast Carcinomas: A Phase II Trial</title><author>Medina-Franco, Heriberto ; Soto-Germes, Santos ; Ulloa-Gómez, José L. ; Romero-Trejo, Cecilia ; Uribe, Norma ; Ramirez-Alvarado, Carlos A. ; Robles-Vidal, Carlos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-97991824be898dd5ca73d718eb19c4f43b579ed2f14a29b53a1df06736d63d113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Breast Neoplasms - therapy</topic><topic>Breast Oncology</topic><topic>Carcinoma, Ductal, Breast - therapy</topic><topic>Catheter Ablation</topic><topic>Female</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Medina-Franco, Heriberto</creatorcontrib><creatorcontrib>Soto-Germes, Santos</creatorcontrib><creatorcontrib>Ulloa-Gómez, José L.</creatorcontrib><creatorcontrib>Romero-Trejo, Cecilia</creatorcontrib><creatorcontrib>Uribe, Norma</creatorcontrib><creatorcontrib>Ramirez-Alvarado, Carlos A.</creatorcontrib><creatorcontrib>Robles-Vidal, Carlos</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Medina-Franco, Heriberto</au><au>Soto-Germes, Santos</au><au>Ulloa-Gómez, José L.</au><au>Romero-Trejo, Cecilia</au><au>Uribe, Norma</au><au>Ramirez-Alvarado, Carlos A.</au><au>Robles-Vidal, Carlos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiofrequency Ablation of Invasive Breast Carcinomas: A Phase II Trial</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2008-06-01</date><risdate>2008</risdate><volume>15</volume><issue>6</issue><spage>1689</spage><epage>1695</epage><pages>1689-1695</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
Local ablative therapy of breast cancer represents the next frontier in the minimally invasive breast-conservation treatment. We conducted a phase II trial to evaluate radiofrequency ablation (RFA) of invasive breast carcinomas.
Methods
Consecutive patients from two Mexican Institutions with invasive breast cancers < 4 cm, with no multicentric tumors and no previous chemotherapy were included in this trial. Under ultrasound guidance, the tumor and a 5 mm margin of surrounding breast tissue were ablated with saline-cooled RFA electrode followed by surgical resection. Routine pathologic analysis and viability evaluation with NADPH-diaphorase stain were performed to assess tumor ablation. Procedure-associated morbidity was recorded.
Results
Twenty-five patients were included. Mean patient age was 55.3 years (range 42–89 years). Mean tumor size was 2.08 cm (range 0.9–3.8 cm). Fourteen tumors (56%) were <2 cm. The mean ablation time was 11 minutes using a mean power of 35 W. During ablation, the tumors become progressively echogenic that corresponded with the region of severe RFA injury at pathologic examination. Of the 25 patients treated, NADPH stain showed no evidence of viable malignant cells in 19 patients (76%), with significant difference between tumors <2 cm (complete necrosis in 13 of 14 cases, 92.8%) vs. those >2 cm (complete necrosis 6 of 11 cases, 54.5%) (
P
< .05). No significant morbidity was recorded.
Conclusions
RFA is a promising minimally invasive treatment of small breast carcinomas, as it can achieve effective cell killing with a low complication rate. Further studies are necessary to optimize the technique and evaluate its future role as local therapy for breast cancer.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>18363072</pmid><doi>10.1245/s10434-008-9875-4</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2008-06, Vol.15 (6), p.1689-1695 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69194089 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Breast Neoplasms - therapy Breast Oncology Carcinoma, Ductal, Breast - therapy Catheter Ablation Female Humans Medicine Medicine & Public Health Middle Aged Oncology Surgery Surgical Oncology Treatment Outcome |
| title | Radiofrequency Ablation of Invasive Breast Carcinomas: A Phase II Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T01%3A05%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiofrequency%20Ablation%20of%20Invasive%20Breast%20Carcinomas:%20A%20Phase%20II%20Trial&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Medina-Franco,%20Heriberto&rft.date=2008-06-01&rft.volume=15&rft.issue=6&rft.spage=1689&rft.epage=1695&rft.pages=1689-1695&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-008-9875-4&rft_dat=%3Cproquest_cross%3E69194089%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227377875&rft_id=info:pmid/18363072&rfr_iscdi=true |